Course and Correlates of Stigma in Patients on Opioid Agonist Treatment: A Prospective Study from an Outpatient Treatment Program in India

被引:1
|
作者
Ghosh, Abhishek [1 ]
Roub, Fazle [1 ]
Pillai, Renjith R. [1 ]
Mahintamani, Tathagata [1 ]
Basu, Debasish [1 ]
Subodh, B. N. [1 ]
Mattoo, S. K. [1 ]
机构
[1] Postgrad Inst Med Educ & Res, Drug Deaddict & Treatment Ctr, Dept Psychiat, Sect 12, Chandigarh 160012, India
关键词
Buprenorphine; enacted stigma; internalized stigma; opioid dependence; quality of life; SUBSTANCE USE DISORDERS; INTERNALIZED STIGMA; MENTAL-ILLNESS; SELF-STIGMA; INDIVIDUALS; QUALITY; SCALE; ABUSE; MODEL; LIFE;
D O I
10.1177/02537176211012103
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Individuals with opioid dependence experience stigma and discrimination. Stigma can potentially reduce treatment-seeking and negatively affect treatment outcomes. We aimed to study the course of stigma and its correlates among patients receiving opioid agonist treatment (OAT). Methods: We recruited 51 subjects (aged between 18 and 45 years) registered in the OAT clinic from February to September 2019. We excluded subjects dependent on alcohol and other drugs (except for cannabis and tobacco), with severe mental illness, intellectual disability, and organic brain disease. We assessed the internalized and enacted stigma and quality of life at the treatment entry and after 3 months. Relationship of stigma with quality of life, socio-demographic, and other clinical variables were examined at the treatment entry. Results: Mean age of the subjects was 26.7 (+/- 5) years. At the end of three months, 33 (64.7%) patients were retained in the treatment. Internalized stigma correlated negatively with the social and environmental domains of quality of life. The strength of the correlations was modest. No significant correlation was found between demographic and clinical variables and internalized stigma and enacted stigma scores. Both internalized and enacted stigma scores reduced significantly at 3 months follow-up. The significance levels were retained even after controlling for the baseline quality of life scores. Stigma at the treatment entry did not predict early dropout. Conclusion: Despite higher severity at the treatment entry, the level of internalized and enacted stigma reduced significantly within three months of an outpatient-based OAT program.
引用
收藏
页码:246 / 252
页数:7
相关论文
共 50 条
  • [31] Evaluation of an Electronic Medical Record System at an Opioid Agonist Treatment Program
    Brown, Lawrence S., Jr.
    Kritz, Steven
    Lin, Melissa
    Zavala, Roberto
    JOURNAL OF ADDICTION MEDICINE, 2014, 8 (02) : 96 - 101
  • [32] National trends in the Australian opioid agonist treatment program, 2013 to 2022
    Bharat, Chrianna
    Chidwick, Kendal
    Gisev, Natasa
    Farrell, Michael
    Degenhardt, Louisa
    DRUG AND ALCOHOL REVIEW, 2023, 42 : S40 - S40
  • [33] Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program
    Gordon, Adam J.
    Lo-Ciganic, Wei-Hsuan
    Cochran, Gerald
    Gellad, Walid F.
    Cathers, Terri
    Kelley, David
    Donohue, Julie M.
    JOURNAL OF ADDICTION MEDICINE, 2015, 9 (06) : 470 - 477
  • [34] Differential time course of effects of κ-opioid agonist treatment on dynorphin a levels and κ-opioid receptor density
    Claudio D’Addario
    Manuela Di Benedetto
    Sari Izenwasser
    Sanzio Candeletti
    Patrizia Romualdi
    Journal of Molecular Neuroscience, 2004, 24 : 307 - 314
  • [35] Differential time course of effects of κ-opioid agonist treatment on dynorphin A levels and κ-opioid receptor density
    D'Addario, C
    Di Benedetto, M
    Izenwasser, S
    Candeletti, S
    Romualdi, P
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2004, 24 (02) : 307 - 314
  • [36] Postoperative opioid misuse in patients with opioid use disorders maintained on opioid agonist treatment
    Namiranian, Khodadad
    Siglin, Jonathan
    Sorkin, John David
    Norris, Edward J.
    Aghevli, Minu
    Covington, Edward C.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2020, 109 : 8 - 13
  • [37] Prospective study of retention in opioid agonist treatment and contact with emergency healthcare following release from prisons in Victoria, Australia
    Curtis, Michael
    Wilkinson, Anna L.
    Dietze, Paul
    Stewart, Ashleigh Cara
    Kinner, Stuart A.
    Cossar, Reece David
    Nehme, Emily
    Aitken, Campbell
    Walker, Shelley
    Butler, Tony
    Winter, Rebecca J.
    Smith, Karen
    Stoove, Mark
    EMERGENCY MEDICINE JOURNAL, 2023, 40 (05) : 347 - 354
  • [38] Are patients' goals in treatment associated with expected treatment outcomes? Findings from a mixed-methods study on outpatient pharmacological treatment for opioid use disorder
    Rosic, Tea
    Naji, Leen
    Panesar, Balpreet
    Chai, Darren B.
    Sanger, Nitika
    Dennis, Brittany B.
    Marsh, David C.
    Rieb, Launette
    Worster, Andrew
    Thabane, Lehana
    Samaan, Zainab
    BMJ OPEN, 2021, 11 (01):
  • [39] Factors Affecting Long-term Retention on Opioid Agonist Maintenance Treatment in a Community Drug Treatment Clinic: A Retrospective Cohort Study from India
    Rao, Ravindra
    Gupta, Swati Kedia
    Ramshankar, Prashanth
    Agrawal, Alok
    Ambekar, Atul
    Dhawan, Anju
    AMERICAN JOURNAL ON ADDICTIONS, 2018, 27 (04): : 311 - 311
  • [40] Nasal Opioid Agonist Treatment in Patients with Severe Opioid Dependence: A Case Series
    Vogel, Marc
    Kock, Patrick
    Strasser, Johannes
    Kalbermatten, Christoph
    Binder, Hannes
    Dursteler, Kenneth M.
    Walter, Marc
    Falcato, Luis
    Krausz, Michael
    Kormann, Adrian
    EUROPEAN ADDICTION RESEARCH, 2022, 28 (01) : 80 - 85